{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T06:32:56Z","timestamp":1720679576587},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2016,10,24]],"date-time":"2016-10-24T00:00:00Z","timestamp":1477267200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,10,24]],"date-time":"2016-10-24T00:00:00Z","timestamp":1477267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1038\/bmt.2016.227","type":"journal-article","created":{"date-parts":[[2016,10,24]],"date-time":"2016-10-24T13:53:53Z","timestamp":1477317233000},"page":"1617-1619","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Minimal detectable disease confirmed by flow cytometry and poor outcome after autologous stem cell transplantation in peripheral T-Cell lymphomas"],"prefix":"10.1038","volume":"51","author":[{"given":"J","family":"Gauthier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Holmberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W","family":"Bensinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A K","family":"Gopal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O","family":"Press","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Maloney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D J","family":"Green","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B G","family":"Till","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Byelykh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Shustov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,10,24]]},"reference":[{"key":"BFbmt2016227_CR1","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"SH Swerdlow","year":"2008","unstructured":"Swerdlow SH, CE HN et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. International Agency for Research on Cancer: Lyon, France, 2008."},{"key":"BFbmt2016227_CR2","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.1182\/blood.V89.12.4514","volume":"89","author":"A Melnyk","year":"1997","unstructured":"Melnyk A, Rodriguez A, Pugh WC, Cabannillas F . Evaluation of the revised European-American lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma. Blood 1997; 89: 4514\u20134520.","journal-title":"Blood"},{"key":"BFbmt2016227_CR3","first-page":"76","volume":"92","author":"C Gisselbrecht","year":"1998","unstructured":"Gisselbrecht C, Gaulard P, Lepage E, Coiffier B, Briere J, Haioun C et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas Groupe d'Etudes des Lymphomes de l'Adulte (GELA). Blood 1998; 92: 76\u201382.","journal-title":"Blood"},{"key":"BFbmt2016227_CR4","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1093\/annonc\/mdh392","volume":"15","author":"KJ Savage","year":"2004","unstructured":"Savage KJ, Chhanabhai M, Gascoyne RD, Connors JM . Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol 2004; 15: 1467\u20131475.","journal-title":"Ann Oncol"},{"key":"BFbmt2016227_CR5","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ctrv.2012.03.011","volume":"39","author":"J Yared","year":"2013","unstructured":"Yared J, Kimball A . The role of high dose chemotherapy and autologous stem-cell transplantation in peripheral T-cell lymphoma: a review of the literature and new perspectives. Cancer Treat Rev 2013; 39: 51\u201359.","journal-title":"Cancer Treat Rev"},{"key":"BFbmt2016227_CR6","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1182\/blood-2013-09-526202","volume":"123","author":"C Damm-Welk","year":"2014","unstructured":"Damm-Welk C, Mussolin L, Zimmermann M, Pillon M, Klapper W, Oschlies I et al. Early assessment of minimal residual disease identifies patients at very high relapse risk in NPM-ALK-positive anaplastic large-cell lymphoma. Blood 2014; 123: 334\u2013337.","journal-title":"Blood"},{"key":"BFbmt2016227_CR7","doi-asserted-by":"crossref","first-page":"680","DOI":"10.5858\/2006-130-680-CACFCI","volume":"130","author":"B Wood","year":"2006","unstructured":"Wood B . 9-color and 10-color flow cytometry in the clinical laboratory. Arch Pathol Lab Med 2006; 130: 680\u2013690.","journal-title":"Arch Pathol Lab Med"},{"key":"BFbmt2016227_CR8","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/cytob.21178","volume":"88","author":"D Wu","year":"2015","unstructured":"Wu D, Allen CT, Fromm JR . Flow cytometry of ALK-negative anaplastic large cell lymphoma of breast implant-associated effusion and capsular tissue. Cytometry B Clin Cytom 2015; 88: 58\u201363.","journal-title":"Cytometry B Clin Cytom"},{"key":"BFbmt2016227_CR9","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1182\/blood.V98.1.165","volume":"98","author":"AW Langerak","year":"2001","unstructured":"Langerak AW, van Den Beemd R, Wolvers-Tettero IL, Boor PP, van Lochem EG, Hooijkaas H et al. Molecular and flow cytometric analysis of the Vbeta repertoire for clonality assessment in mature TCRalphabeta T-cell proliferations. Blood 2001; 98: 165\u2013173.","journal-title":"Blood"},{"key":"BFbmt2016227_CR10","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1093\/ajcp\/aqw015","volume":"145","author":"D Wu","year":"2016","unstructured":"Wu D, Anderson MM, Othus M, Wood BL . Clinical experience with modified, single-tube T-cell receptor vbeta flow cytometry analysis for T-cell clonality. Am J Clin Pathol 2016; 145: 467\u2013485.","journal-title":"Am J Clin Pathol"},{"key":"BFbmt2016227_CR11","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1182\/blood-2013-12-516245","volume":"123","author":"AJ Moskowitz","year":"2014","unstructured":"Moskowitz AJ, Lunning MA, Horwitz SM . How I treat the peripheral T-cell lymphomas. Blood 2014; 123: 2636\u20132644.","journal-title":"Blood"},{"key":"BFbmt2016227_CR12","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/j.1365-2141.2004.05144.x","volume":"127","author":"A Dogan","year":"2004","unstructured":"Dogan A, Morice WG . Bone marrow histopathology in peripheral T-cell lymphomas. Br J Haematol 2004; 127: 140\u2013154.","journal-title":"Br J Haematol"},{"key":"BFbmt2016227_CR13","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1089\/scd.1.1992.1.225","volume":"1","author":"TJ Moss","year":"1992","unstructured":"Moss TJ, Ross AA . The risk of tumor cell contamination in peripheral blood stem cell collections. J Hematother 1992; 1: 225\u2013232.","journal-title":"J Hematother"},{"key":"BFbmt2016227_CR14","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1089\/15258160151135042","volume":"10","author":"W Kruger","year":"2001","unstructured":"Kruger W, Kroger N, Togel F, Badbaran A, Renges H, Gieseking F et al. Influence of preharvest tumor cell contamination in bone marrow or blood does not predict resultant tumor cell contamination of granulocyte colony-stimulating factor mobilized stem cells. J Hematother Stem Cell Res 2001; 10: 303\u2013307.","journal-title":"J Hematother Stem Cell Res"},{"key":"BFbmt2016227_CR15","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/sj.bmt.1704133","volume":"32","author":"R Syme","year":"2003","unstructured":"Syme R, Stewart D, Rodriguez-Galvez M, Luider J, Auer Y, Klassen J et al. Micrometastases in apheresis products predict shorter progression-free and overall survival in patients with breast cancer undergoing high-dose chemotherapy (HDCT) and autologous blood stem cell transplantation (ABSCT). Bone Marrow Transplant 2003; 32: 307\u2013311.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2016227_CR16","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1309\/QF6N-VAQW-N74H-4JE2","volume":"116","author":"S Jamal","year":"2001","unstructured":"Jamal S, Picker LJ, Aquino DB, McKenna RW, Dawson DB, Kroft SH . Immunophenotypic analysis of peripheral T-cell neoplasms. A multiparameter flow cytometric approach. Am J Clin Pathol 2001; 116: 512\u2013526.","journal-title":"Am J Clin Pathol"},{"key":"BFbmt2016227_CR17","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1309\/AJCPV2D1DDSGJDBW","volume":"135","author":"P Tembhare","year":"2011","unstructured":"Tembhare P, Yuan CM, Xi L, Morris JC, Liewehr D, Venzon D et al. Flow cytometric immunophenotypic assessment of T-cell clonality by Vbeta repertoire analysis: detection of T-cell clonality at diagnosis and monitoring of minimal residual disease following therapy. Am J Clin Pathol 2011; 135: 890\u2013900.","journal-title":"Am J Clin Pathol"},{"key":"BFbmt2016227_CR18","doi-asserted-by":"publisher","first-page":"134ra63","DOI":"10.1126\/scitranslmed.3003656","volume":"4","author":"D Wu","year":"2012","unstructured":"Wu D, Sherwood A, Fromm JR, Winter SS, Dunsmore KP, Loh ML et al. High-throughput sequencing detects minimal residual disease in acute T lymphoblastic leukemia. Sci Transl Med 2012; 4: 134ra63.","journal-title":"Sci Transl Med"},{"key":"BFbmt2016227_CR19","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1309\/AJCP5TYGBVW4ZITR","volume":"141","author":"JA Schumacher","year":"2014","unstructured":"Schumacher JA, Duncavage EJ, Mosbruger TL, Szankasi PM, Kelley TW . A comparison of deep sequencing of TCRG rearrangements vs traditional capillary electrophoresis for assessment of clonality in T-Cell lymphoproliferative disorders. Am J Clin Pathol 2014; 141: 348\u2013359.","journal-title":"Am J Clin Pathol"},{"key":"BFbmt2016227_CR20","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/j.1365-2141.2011.08619.x","volume":"154","author":"A Shustov","year":"2011","unstructured":"Shustov A, Cherian S, Shaw A, Lupinacci TA, Maloney D, Holmberg L et al. In-vivo purging of the circulating clonal T-cells with Alemtuzumab prior to autologous peripheral blood hematopoietic cell mobilization and transplantation. Br J Haematol 2011; 154: 415\u2013418.","journal-title":"Br J Haematol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt2016227.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2016227","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2016227.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T19:28:18Z","timestamp":1648063698000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt2016227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,24]]},"references-count":20,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["BFbmt2016227"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2016.227","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,24]]},"assertion":[{"value":"24 October 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Gopal AK: Merck: Research Funding; Emergent\/Abbott: Research Funding; Cephalon\/Teva: Research Funding; BioMarin: Research Funding; Sanofi-Aventis: Honoraria; Millenium: Honoraria, Research Funding; Seattle Genetics: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Research Funding; Pfizer: Consultancy, Research Funding; Spectrum: Consultancy, Research Funding; Gilead: Consultancy, Research Funding; Piramal: Research Funding; Biogen Idec, BMS: Research Funding. Maloney D: Juno Therapeutics: Research Funding; Roche\/Genentech: Honoraria; Janssen Scientific Affairs: Honoraria; Seattle Genetics: Honoraria. Till: Roche-Genentech: Research Funding. Shustov A: Celgene: Honoraria and consultancy, Spectrum and BMS: consultancy.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}